AOBiome Therapeutics is a clinical-stage life sciences company focused on developing innovative therapies that harness the power of Ammonia Oxidizing Bacteria (AOB) to address chronic inflammatory conditions. The company operates in the biopharmaceutical market, targeting conditions such as hypertension, acne, allergic rhinitis, migraine, eczema, and rosacea. AOBiome's proprietary product candidates utilize a single strain of AOB, a naturally occurring microorganism with well-characterized biochemical properties essential to human health. These candidates aim to restore the symbiotic relationship between bacteria and humans, which has been disrupted by modern lifestyle factors such as the use of surfactants and antibiotics. AOBiome's business model involves advancing its product candidates through clinical trials, with the goal of obtaining regulatory approval and commercializing these therapies. The company generates revenue through partnerships, licensing agreements, and eventually, product sales. To date, AOBiome has completed six Phase 2 clinical programs and multiple preclinical programs, enrolling over 1,000 patients since 2016.

Keywords: Ammonia Oxidizing Bacteria, chronic inflammatory conditions, biopharmaceutical, clinical trials, hypertension, acne, allergic rhinitis, migraine, eczema, rosacea.